OSR Holdings Plunges 10.98% on Strategic Acquisition of WORIO

OSR Holdings' stock price dropped 10.98% in pre-market trading on July 31, 2025, marking a significant decline for the company.

OSR Holdings has announced a strategic update on its term sheet with Woori IO (WORIO), a South Korean medical device company specializing in noninvasive glucose monitoring technology. The acquisition will make WORIO a wholly-owned subsidiary of OSRH's Korean affiliate, OSRK. This move positions OSRH as a key player in the rapidly growing noninvasive glucose monitoring market, which is projected to reach $40 billion by 2030.

Under the terms of the agreement, WORIO shareholders will receive OSRK shares with a conditional right to exchange them for OSRH common stock if OSRH's share price reaches $10.00 within three years. This represents a nearly 10x premium over current trading levels, demonstrating OSRH's confidence in the potential value creation from this acquisition. WORIO's technology, which uses near-infrared spectroscopy for needle-free glucose measurement, is suitable for integration into smartwatches and has completed a proof-of-concept study, with plans for a larger confirmatory study for Korean regulatory approval.

This acquisition is strategically significant as it allows OSRH to enter the noninvasive glucose monitoring market with a unique shareholder-aligned deal structure. The conditional share exchange mechanism protects OSRH shareholders from immediate dilution while providing WORIO shareholders with substantial upside if the combined entity succeeds in commercializing the technology. The 6-month exclusivity period also allows OSRH to conduct thorough due diligence while securing its position in this high-demand sector.